Please visit us at ENDOExpo 2024 (Booth 626)

NEW DATA: A Real-world Observational Study Fully Supports Test Performance

Molecular Diagnosis of Medullary Thyroid Carcinoma

USCAP 2018, Vancouver, BC, Canada
  • Medullary thyroid carcinoma (MTC) is a rare neuroendocrine cancer originating from parafollicular C-cells that produce calcitonin
  • MTC accounts for 5%-10% of all thyroid carcinomas (Note: Prevalence was also found to be lower, with a range of 2%-5%)
  • Age and stage of disease at the time of diagnosis are the main prognostic indicators
  • Diagnosis of MTC can be challenging in thyroid fine needle aspiration (FNA) cytology specimens
  • Cytologic appearance of MTC can overlap with other thyroid neoplasms, thereby preventing a definitive diagnosis
  • This study was designed to identify distinguishing molecular characteristics of MTC versus other thyroid neoplasms, for use in limited specimens such as FNA biopsies

Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.